Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Lyra Therapeutics (LYRA)
NASDAQ:LYRA
Lyra Therapeutics (LYRA) Stock Price & Analysis
132 Followers
LYRA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.35 - $8.18
Previous Close$2.75
Volume34.86K
Average Volume (3M)33.27K
Market CapN/A
Enterprise ValueN/A
Total Cash (Recent Filing)$109.56M
Total Debt (Recent Filing)$657.00K
Price to Earnings (P/E)-1.0
Beta-1.12
Next EarningsMar 08, 2023
EPS Estimate-$0.42
Next Dividend Ex-DateN/A
Dividend YieldN/A
1Y Price TargetN/A
EPS (TTM)-2.79
Shares Outstanding31,827,008
R-Squared0.02
Standard Deviation0.19
10 Day Avg. Volume33,964
30 Day Avg. Volume33,273
Price to Book (P/B)0.97
Price to Sales (P/S)68.27
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-2.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Price Target UpsideN/A
Rating ConsensusN/A
Alpha-0.03
Number of Analyst Covering0
Lyra Therapeutics News
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LYRA FAQ
What was Lyra Therapeutics’s price range in the past 12 months?
Lyra Therapeutics lowest stock price was $2.35 and its highest was $8.18 in the past 12 months.
What is Lyra Therapeutics’s market cap?
Currently, no data Available
When is Lyra Therapeutics’s upcoming earnings report date?
Lyra Therapeutics’s upcoming earnings report date is Mar 08, 2023 which is in 30 days.
How were Lyra Therapeutics’s earnings last quarter?
Lyra Therapeutics released its earnings results on Nov 15, 2022. The company reported -$0.4 earnings per share for the quarter, beating the consensus estimate of -$0.44 by $0.04.
Is Lyra Therapeutics overvalued?
According to Wall Street analysts Lyra Therapeutics’s price is currently Overvalued.
Does Lyra Therapeutics pay dividends?
Lyra Therapeutics does not currently pay dividends.
What is Lyra Therapeutics’s EPS estimate?
Lyra Therapeutics’s EPS estimate is -$0.42.
How many shares outstanding does Lyra Therapeutics have?
Lyra Therapeutics has 31,827,007 shares outstanding.
What happened to Lyra Therapeutics’s price movement after its last earnings report?
Lyra Therapeutics reported an EPS of -$0.4 in its last earnings report, beating expectations of -$0.44. Following the earnings report the stock price went down -2.5%.
Which hedge fund is a major shareholder of Lyra Therapeutics?
Among the largest hedge funds holding Lyra Therapeutics’s share is Perceptive Advisors LLC. It holds Lyra Therapeutics’s shares valued at 46M.
---
Lyra Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.57%
12-Months-Change
Fundamentals
Return on Equity
-77.86%
Trailing 12-Months
Asset Growth
76.30%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Lyra Therapeutics
Lyra Therapeutics Inc a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat diseases. The company's technology platform, XTreo, is designed to precisely and consistently deliver medicines directly to the affected tissue for sustained periods with a single administration.
---
---